A clinical study involving TNFerade biologic (adenovector delivering tumor necrosis factor-alpha (TNF-α) to tumor cells) in locally advanced pancreatic cancer patients confirmed its safety but failed to demonstrate an extension in survival [61]. The gene discussed is TNF; the disease is familial pancreatic carcinoma.